Impact of perioperative high mobility group box chromosomal protein 1 expression on long-term outcomes in patients with esophageal squamous cell carcinoma.
Aged
Biomarkers
/ blood
Biosimilar Pharmaceuticals
Esophageal Neoplasms
/ diagnosis
Esophageal Squamous Cell Carcinoma
/ diagnosis
Esophagectomy
Female
Gene Expression
HMGB1 Protein
/ blood
Humans
Male
Perioperative Period
Postoperative Complications
/ diagnosis
Postoperative Period
Prognosis
Time Factors
Treatment Outcome
cytokine production
esophagectomy
high mobility group box chromosomal protein 1
pulmonary complication
surgical stress
systemic inflammatory response syndrome
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
12
08
2019
revised:
02
09
2019
accepted:
05
09
2019
pubmed:
10
9
2019
medline:
8
10
2020
entrez:
10
9
2019
Statut:
ppublish
Résumé
High mobility group box chromosomal protein-1 (HMGB-1) is a potential late mediator of sepsis and a possible risk factor for postoperative pulmonary complications after esophagectomy. This study aimed to determine the relationship between HMGB-1 and clinicopathological factors and long-term prognosis after esophagectomy for esophageal cancer. We measured perioperative serum HMGB-1 levels using ELISA and HMGB-1 protein by immunohistochemistry expression in resected specimens. Postoperative serum HMGB-1 levels were significantly higher than preoperative levels. Preoperative serum HMGB-1 levels were significantly higher in patients with more intraoperative bleeding, longer intensive care unit stays, and postoperative pneumonia. Postoperative serum HMGB-1 levels were significantly higher in older patients and those with longer operation time and more intraoperative bleeding. There were significant differences in long-term outcomes according to postoperative but not preoperative serum HMGB-1 levels. Multivariate analysis demonstrated that advanced pathological stage, postoperative pulmonary complications, and higher postoperative serum HMGB-1 levels were independently associated with relapse-free survival and overall survival. Preoperative serum HMGB-1 levels were significantly higher in patients with high HMGB-1 expression than those with low HMGB-1 expression by immunohistochemistry, whereas such statistical differences were not observed in postoperative serum HMGB-1. There were no differences in relapse-free survival and overall survival according to HMGB-1 expression by immunohistochemistry. Serum HMGB-1 levels were significantly increased after esophagectomy for esophageal cancer. Elevated postoperative serum HMGB-1, which was associated not only with poor long-term but also short-term outcomes such as postoperative complications, might serve as a potential marker for prognosis in esophageal cancer.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
High mobility group box chromosomal protein-1 (HMGB-1) is a potential late mediator of sepsis and a possible risk factor for postoperative pulmonary complications after esophagectomy. This study aimed to determine the relationship between HMGB-1 and clinicopathological factors and long-term prognosis after esophagectomy for esophageal cancer.
METHODS
METHODS
We measured perioperative serum HMGB-1 levels using ELISA and HMGB-1 protein by immunohistochemistry expression in resected specimens.
RESULTS
RESULTS
Postoperative serum HMGB-1 levels were significantly higher than preoperative levels. Preoperative serum HMGB-1 levels were significantly higher in patients with more intraoperative bleeding, longer intensive care unit stays, and postoperative pneumonia. Postoperative serum HMGB-1 levels were significantly higher in older patients and those with longer operation time and more intraoperative bleeding. There were significant differences in long-term outcomes according to postoperative but not preoperative serum HMGB-1 levels. Multivariate analysis demonstrated that advanced pathological stage, postoperative pulmonary complications, and higher postoperative serum HMGB-1 levels were independently associated with relapse-free survival and overall survival. Preoperative serum HMGB-1 levels were significantly higher in patients with high HMGB-1 expression than those with low HMGB-1 expression by immunohistochemistry, whereas such statistical differences were not observed in postoperative serum HMGB-1. There were no differences in relapse-free survival and overall survival according to HMGB-1 expression by immunohistochemistry. Serum HMGB-1 levels were significantly increased after esophagectomy for esophageal cancer.
CONCLUSION
CONCLUSIONS
Elevated postoperative serum HMGB-1, which was associated not only with poor long-term but also short-term outcomes such as postoperative complications, might serve as a potential marker for prognosis in esophageal cancer.
Substances chimiques
Biomarkers
0
Biosimilar Pharmaceuticals
0
HMGB1 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
788-794Informations de copyright
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Haga Y, Beppu T, Doi K et al. Systemic inflammatory response syndrome and organ dysfunction following gastrointestinal surgery. Crit. Care Med. 1997; 25: 1994-2000.
Ono S, Tsujimoto H, Hiraki S et al. Effects of neutrophil elastase inhibitor on progression of acute lung injury following esophagectomy. World J. Surg. 2007; 31: 1996-2001.
Tsujimoto H, Takahata R, Nomura S et al. Video-assisted thoracoscopic surgery for esophageal cancer attenuates postoperative systemic responses and pulmonary complications. Surgery 2012; 151: 667-673.
Tsujimoto H, Ono S, Chochi K, Sugasawa H, Ichikura T, Mochizuki H. Preoperative chemoradiotherapy for esophageal cancer enhances the postoperative systemic inflammatory response. Jpn. J. Clin. Oncol. 2006; 36: 632-637.
Tsutsui S, Moriguchi S, Morita M et al. Multivariate analysis of postoperative complications after esophageal resection. Ann. Thorac. Surg. 1992; 53: 1052-1056.
Nagawa H, Kobori O, Muto T. Prediction of pulmonary complications after transthoracic oesophagectomy. Br. J. Surg. 1994; 81: 860-862.
Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
Takahata R, Ono S, Tsujimoto H et al. Preoperative chemoradiation therapy for esophageal cancer is a risk factor for the elevation of high mobility group box-1, leading to an increase in postoperative severe pulmonary complications. Dis. Esophagus 2016; 29: 70-78.
Suda K, Kitagawa Y, Ozawa S et al. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery? Dis. Esophagus 2006; 19: 5-9.
Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 2010; 1799: 131-140.
Liu Y, Xie C, Zhang X et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur. J. Cancer 2010; 46: 3007-3015.
Choi YR, Kim H, Kang HJ et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res. 2003; 63: 2188-2193.
Brierley J, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours, eighth edn. New Jersey: Wiley-Blackwell, 2016.
Bitto A, Barone M, David A et al. High mobility group box-1 expression correlates with poor outcome in lung injury patients. Pharmacol. Res. 2010; 61: 116-120.
Cheng BQ, Jia CQ, Liu CT et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig. Liver Dis. 2008; 40: 446-452.
Kim JY, Park JS, Strassheim D et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 288: L958-L965.
Lutz W, Stetkiewicz J. High mobility group box 1 protein as a late-acting mediator of acute lung inflammation. Int. J. Occup. Med. Environ. Health 2004; 17: 245-254.
Takahata R, Ono S, Tsujimoto H et al. Postoperative serum concentrations of high mobility group box chromosomal protein-1 correlates to the duration of SIRS and pulmonary dysfunction following gastrointestinal surgery. J. Surg. Res. 2011; 170: e135-e140.
Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 2000; 165: 2950-2954.
Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 2007; 3: 382-390.
Brett J, Schmidt AM, Yan SD et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 1993; 143: 1699-1712.
Sharma A, Ray R, Rajeswari MR. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest. 2008; 26: 843-851.
Wang W, Jiang H, Zhu H et al. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol. Lett. 2013; 5: 884-888.
Suren D, Yildirim M, Demirpence O et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med. Sci. Monit. 2014; 20: 530-537.
Suren D, Arda Gokay A, Sayiner A. High Mobility Group Box 1 (HMGB1) expression in gastric adenocarcinomas. J. B.U.ON. 2018; 23: 422-427.
Li B, Song TN, Wang FR et al. Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1(+) TAM expansion. Oncogene 2019; 8: 17.
Di X, He G, Chen H et al. High-mobility group box 1 protein modulated proliferation and radioresistance in esophageal squamous cell carcinoma. J. Gastroenterol. Hepatol. 2019; 34: 728-735.
Chuangui C, Peng T, Zhentao Y. The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol. Oncol. Res. 2012; 18: 1021-1027.
Xu YF, Liu ZL, Pan C et al. HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium. Oncogene 2019; 38: 868-880.
Li P, Xu M, Cai H, Thapa N, He C, Song Z. The effect of HMGB1 on the clinicopathological and prognostic features of cervical cancer. Biosci. Rep. 2019; 39: pii: BSR20181016. https://doi.org/10.1042/BSR20181016.
Akaike H, Kono K, Sugai H et al. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007; 27: 449-457.
Lagarde SM, de Boer JD, ten Kate FJ, Busch OR, Obertop H, van Lanschot JJ. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann. Surg. 2008; 247: 71-76.
Shimada H, Fukagawa T, Haga Y, Oba K. Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature. Ann. Gastroenterol. Surg. 2017; 1: 11-23.
Tsujimoto H, Ichikura T, Ono S et al. Impact of postoperative infection on long-term survival after potentially curative resection for gastric cancer. Ann. Surg. Oncol. 2009; 16: 311-318.
Ishibashi Y, Tsujimoto H, Hiraki S et al. Prognostic Value of Preoperative Systemic Immunoinflammatory Measures in Patients with Esophageal Cancer. Ann. Surg. Oncol. 2018; 25: 3288-3299.